BACKGROUND: The authors tested whether cocaine depresses mitochondrial acylcarnitine exchange and if a drug that enhances glucose metabolism could protect against cocaine-induced cardiac dysfunction. METHODS: Oxygen consumption with and without cocaine was compared in rat cardiac mitochondria using octanoylcarnitine (lipid) or pyruvate (nonlipid) substrates. Isolated hearts from rats with or without a pioglitazone-supplemented diet were exposed to cocaine. RESULTS: The 0.5 mM cocaine inhibited respiration supported by octanoylcarnitine (82 ± 10.4 and 45.7 ± 4.24 ngatomO min⁻¹ · mg⁻¹ · protein ± SEM, for control and cocaine treatment, respectively; P < 0.02) but not pyruvate-supported respiration (281 ± 12.5 and 267 ± 12.7 ngatomO min⁻¹ · mg⁻¹ · protein ± SEM; P = 0.45). Cocaine altered contractility, lusitropy, coronary resistance, and lactate production in isolated heart. These effects were each blunted in pioglitazone-treated hearts. The pioglitazone diet attenuated the drop in the rate-pressure product (P = 0.002), cocaine-induced diastolic dysfunction (P = 0.04), and myocardial vascular resistance (P = 0.05) compared with that of controls. Lactate production was higher in pretreated hearts (P = 0.008) and in ventricular myocytes cultured with pioglitazone (P = 0.0001). CONCLUSIONS: Cocaine inhibited octanoylcarnitine-supported mitochondrial respiration. A pioglitazone diet significantly attenuated the effects of cocaine on isolated heart. The authors postulate that inhibition of acylcarnitine exchange could contribute to cocaine-induced cardiac dysfunction and that metabolic modulation warrants additional study.
BACKGROUND: The authors tested whether cocaine depresses mitochondrial acylcarnitine exchange and if a drug that enhances glucose metabolism could protect against cocaine-induced cardiac dysfunction. METHODS:Oxygen consumption with and without cocaine was compared in rat cardiac mitochondria using octanoylcarnitine (lipid) or pyruvate (nonlipid) substrates. Isolated hearts from rats with or without a pioglitazone-supplemented diet were exposed to cocaine. RESULTS: The 0.5 mM cocaine inhibited respiration supported by octanoylcarnitine (82 ± 10.4 and 45.7 ± 4.24 ngatomO min⁻¹ · mg⁻¹ · protein ± SEM, for control and cocaine treatment, respectively; P < 0.02) but not pyruvate-supported respiration (281 ± 12.5 and 267 ± 12.7 ngatomO min⁻¹ · mg⁻¹ · protein ± SEM; P = 0.45). Cocaine altered contractility, lusitropy, coronary resistance, and lactate production in isolated heart. These effects were each blunted in pioglitazone-treated hearts. The pioglitazone diet attenuated the drop in the rate-pressure product (P = 0.002), cocaine-induced diastolic dysfunction (P = 0.04), and myocardial vascular resistance (P = 0.05) compared with that of controls. Lactate production was higher in pretreated hearts (P = 0.008) and in ventricular myocytes cultured with pioglitazone (P = 0.0001). CONCLUSIONS:Cocaine inhibited octanoylcarnitine-supported mitochondrial respiration. A pioglitazone diet significantly attenuated the effects of cocaine on isolated heart. The authors postulate that inhibition of acylcarnitine exchange could contribute to cocaine-induced cardiac dysfunction and that metabolic modulation warrants additional study.
Authors: Leonard S Golfman; Christopher R Wilson; Saumya Sharma; Mathias Burgmaier; Martin E Young; Patrick H Guthrie; Melissa Van Arsdall; Julia V Adrogue; Kathleen K Brown; Heinrich Taegtmeyer Journal: Am J Physiol Endocrinol Metab Date: 2005-03-29 Impact factor: 4.310
Authors: D L Feinstein; A Spagnolo; C Akar; G Weinberg; P Murphy; V Gavrilyuk; C Dello Russo Journal: Biochem Pharmacol Date: 2005-07-15 Impact factor: 5.858
Authors: Neda Rasouli; Ulrika Raue; Leslie M Miles; Tong Lu; Gina B Di Gregorio; Steven C Elbein; Philip A Kern Journal: Am J Physiol Endocrinol Metab Date: 2005-01-04 Impact factor: 4.310
Authors: T A Buchanan; W P Meehan; Y Y Jeng; D Yang; T M Chan; J L Nadler; S Scott; R K Rude; W A Hsueh Journal: J Clin Invest Date: 1995-07 Impact factor: 14.808
Authors: Barbara Brunmair; Katrin Staniek; Florian Gras; Nicole Scharf; Aleksandra Althaym; Renate Clara; Michael Roden; Erich Gnaiger; Hans Nohl; Werner Waldhäusl; Clemens Fürnsinn Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Michael R Fettiplace; Adrian Pichurko; Richard Ripper; Bocheng Lin; Katarzyna Kowal; Kinga Lis; David Schwartz; Douglas L Feinstein; Israel Rubinstein; Guy Weinberg Journal: Acad Emerg Med Date: 2015-04-23 Impact factor: 3.451